101 related articles for article (PubMed ID: 2306706)
1. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
2. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
4. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
5. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
6. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice.
Braakhuis BJ; van Dongen GA; Bagnay M; van Walsum M; Snow GB
Head Neck; 1989; 11(6):511-5. PubMed ID: 2584006
[TBL] [Abstract][Full Text] [Related]
7. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
Urba S; Doroshow J; Cripps C; Robert F; Velez-Garcia E; Dallaire B; Adams D; Carlson R; Grillo-Lopez A; Gyves J
Cancer Chemother Pharmacol; 1992; 31(2):167-9. PubMed ID: 1451236
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor and differentiation-inducing activity of N,N-dimethylformamide (DMF) in head-and-neck cancer xenografts.
van Dongen GA; Braakhuis BJ; Leyva A; Hendriks HR; Kipp BB; Bagnay M; Snow GB
Int J Cancer; 1989 Feb; 43(2):285-92. PubMed ID: 2465278
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.
de Forni M; Chabot GG; Armand JP; Fontana X; Recondo G; Domenge C; Carde P; Barbu M; Gouyette A
Eur J Cancer; 1993; 29A(7):983-8. PubMed ID: 8499153
[TBL] [Abstract][Full Text] [Related]
14. Activity of differentiation-inducing agents and conventional drugs in head and neck cancer xenografts.
van Dongen G; Braakhuis BJ; Bagnay M; Leyva A; Snow GB
Acta Otolaryngol; 1988; 105(5-6):488-93. PubMed ID: 2456664
[TBL] [Abstract][Full Text] [Related]
15. Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts.
Shen HS; Chen SF; Behrens DL; Whitney CC; Dexter DL; Forbes M
Cancer Chemother Pharmacol; 1988; 22(3):183-6. PubMed ID: 3409452
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
17. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; Kegel A; Welters MJ
Cancer Lett; 1994 Jun; 81(2):151-4. PubMed ID: 7912164
[TBL] [Abstract][Full Text] [Related]
18. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
Brown DH; Braakhuis BJ; van Dongen GA; van Walsum M; Bagnay M; Snow GB
Anticancer Res; 1989; 9(6):1549-52. PubMed ID: 2627109
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
